RESEARCH ARTICLE

# Rigid ureteroscopic lithotripsy versus percutaneous nephrolithotomy for large proximal ureteral stones: A meta-analysis

Qing Wang<sup>1</sup><sup>°</sup>, Jiachao Guo<sup>2</sup><sup>°</sup>, Henglong Hu<sup>1</sup>, Yuchao Lu<sup>1</sup>, Jiaqiao Zhang<sup>1</sup>, Baolong Qin<sup>1</sup>, Yufeng Wang<sup>1</sup>, Zongbiao Zhang<sup>1</sup>, Shaogang Wang<sup>1</sup>\*

1 Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, 2 Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

These authors contributed equally to this work.

\* sgwangtjm@163.com

# Abstract

### Object

To compare the safety and efficacy of rigid ureteroscopic lithotripsy (rigid URSL) and percutaneous nephrolithotomy (PCNL) in treating large proximal ureteral stones.

### Methods

A systematic search of PubMed, EMBASE, Cochrane Library, and Web of Science databases was performed to find out relevant studies. After literature screening according to the predetermined inclusion and exclusion criteria, data of eligible studies was extracted and then a meta-analysis was conducted via RevMan 5.3 software.

### Results

Five randomized controlled trials (RCTs), one prospective and four retrospective cohort studies involving 837 patients were included. Patients underwent rigid URSL were associated with shorter operation time (WMD, -23.66min; 95%CI, -45.00 to -2.32; p = 0.03), shorter hospital stay (WMD, -2.76d; 95%CI, -3.51 to -2.02; p < 0.00001), lower 3rd-day (RR, 0.73; 95%CI, 0.66 to 0.82; p < 0.00001) and 1st-month (RR, 0.82; 95%CI, 0.77 to 0.87; p < 0.00001) stone-free rate, higher risk of conversion to other surgical procedures (RR, 4.28; 95%CI, 1.93 to 9.46; p = 0.0003), higher incidence of migration (RR, 28.49; 95%CI, 9.12 to 89.00; p < 0.00001) and ureteral perforation (RR, 6.06; 95%CI, 1.80 to 20.44; p = 0.004), lower risk of fever (RR, 0.64; 95%CI, 0.42 to 0.97; p = 0.04), transfusion (RR, 0.19; 95%CI, 0.04 to 0.85; p = 0.03) and hematuria (RR, 0.38; 95%CI, 0.25 to 0.57; p < 0.0001). No significant difference was observed in terms of incidence of embolization, pain and ureterostenosis. When cohort studies or studies in which flexible ureteroscopy was used as an intraoperative auxiliary procedure were excluded, we both found that most of the results kept stable.



# G OPEN ACCESS

**Citation:** Wang Q, Guo J, Hu H, Lu Y, Zhang J, Qin B, et al. (2017) Rigid ureteroscopic lithotripsy versus percutaneous nephrolithotomy for large proximal ureteral stones: A meta-analysis. PLoS ONE 12(2): e0171478. doi:10.1371/journal. pone.0171478

Editor: Zheng Li, Peking Union Medical College Hospital, CHINA

Received: August 19, 2016

Accepted: January 2, 2017

Published: February 9, 2017

**Copyright:** © 2017 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are included in the paper.

**Funding:** The authors received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

### Conclusions

Both PCNL and rigid URSL are safe for patients with large proximal ureteral stones while PCNL is more effective in stone clearance.

### Introduction

Large proximal ureteral stones can lead to urinary obstruction, which may be followed with renal function injury and life-threatening sepsis. Timely intervention to remove the stones completely is of great importance while the most appropriate treatment remains controversial.

According to the latest American Urological Association (AUA) Guideline on surgical management of stones, extracorporeal shock wave lithotripsy (SWL) and ureteroscopic lithotripsy (URSL) have been proposed as the first-line treatments for proximal ureteral stones [1]. However, SWL should not be a priority for stones larger than 10mm because of dramatically decreased stone-free rate and requirement of multiple sessions [2,3]. 2016 European Association of Urology (EAU) Guideline indicates that percutaneous nephrolithotomy (PCNL) can be considered in selected cases, such as large (>10mm), impacted proximal ureteral calculi with dilated renal collecting system, or when the ureter is not amenable to retrograde manipulation [4].

Both URSL and PCNL are widely used as minimally-invasive treatments for large proximal ureteral stones. Rigid URSL is the most used ureteroscopy technique and the reported stonefree rate for it in managing upper ureteral stones ranges from 88% to 100% [5,6]. PCNL also shows a high stone clearance rate in proximal ureteral stones since it was introduced into routine clinical practice in 1980s [7,8,9]. Despite the reliable efficiency, each technique has its own limitations. Migration of stones or fragments is the main reason for failure in rigid URSL and further auxiliary procedures, such as flexible URSL and SWL, are often required in this case. PCNL is a more invasive technique, during which bleeding is generally common and 0-20%with an overall of 7% need transfusion [10]. Moreover, adjacent organ injury should not be ignored when referring to PCNL even though the incidence is only about 0.4% [11]. So there comes a question for urologists that which one is better for patients with large proximal ureteral stones. Since 1999, several studies comparing the efficacy and safety of rigid URSL and PCNL in treating large proximal ureteral stones have been carried out [12–21]. As the results of these studies are not totally consistent, a meta-analysis which compares the outcomes of rigid URSL and PCNL should be carried out to provide some advice for urologists and patients in making relevant decisions in the future.

### Materials and methods

### Literature search

We conducted a systematic literature search of Medline (using PubMed as the search engine), Embase (using Ovid as the search engine), Web of Science databases and the Cochrane Library to identify relevant studies in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)[22] in April 2016 and updated in August 2016. The search was performed with the following terms: ("ureteroscope" or "ureteroscopy" or "ureteroscopic lithotripsy" or "ureterolithotripsy" or "retrograde") and ("percutaneous nephrolithotomy" or "percutaneous lithotripsy" or "PCNL" or "PNL" or "PCN" or "antegrade") and ("ureteral calculi" or "ureteral calculus" or "ureteral stone" or "ureteral stones"). No restriction of year or language was imposed. Two independent reviewers screened all the citations and abstracts. Studies involving comparison of rigid URSL and PNL in treating proximal ureteral stones were included for further screening.

**Inclusion criteria and exclusion criteria.** Studies meeting the predetermined criteria were included: (1) patients with large (>10mm) proximal ureteral stones or accompanied with secondary renal stones (<10mm), (2) comparing rigid URSL with PCNL or including a comparison of rigid URSL and PCNL, (3) both surgical techniques should be performed on adults, (4) the full text could be accessed online, (5) reporting at least one of clinical outcomes of interest (described in data extraction part).

Exclusion criteria included: (1) the study was conducted during pregnancy, (2) conference abstracts (because they seemed not methodologically appropriate), (3) no outcome of interest was reported or it was impossible to calculate, (4) the surgical procedure was performed via specialized technique, for example, PCNL in a modified position, tubeless PCNL, or with the aid of patented systems.

Two reviewers independently completed this selection process. Disagreements were resolved by discussion until a consensus was reached.

**Study quality and level of evidence.** The criteria provided by the Oxford Center for Evidence-Based Medicine [23] was used to rate the level of evidence for all studies. The methodological quality of the non-randomized controlled trials (nRCTs) was assessed using the Newcastle-Ottawa Scale [24] and the Cochrane Collaboration's tool [25] was used to assess the risk of bias of randomized controlled trials (RCTs). Two reviewers performed the procedure independently. Disagreements were resolved by discussion until a consensus was reached.

### Data extraction

The following data was extracted independently by two reviewers using a pre-designed data extraction form, which consisted of study name, the first author, year of publication, country, study design, number of patients, stone size, age, gender, stone side and clinical outcomes of interest (the 3<sup>rd</sup>-day or the 1<sup>st</sup>-month stone free rate, operation time, hospital stay, and the incidence of intra- or post-operative complications involving stone migration, ureteral perforation, conversion to other surgical procedure, fever, transfusion, embolization, pain, hematuria and ureterostenosis). Type of ureteroscope and nephroscope and whether a postoperative auxiliary SWL was given to patients with residual stones were also extracted in each study, which was critical for the following subgroup and sensitivity analysis.

### Statistical analysis

A meta-analysis was conducted via RevMan 5.3 software of the Cochrane Collaboration to compare the efficacy and safety of rigid URSL with PCNL in treating large proximal ureteral stones. Relative risk or odds ratio was used for dichotomous data, and weighted or standardized mean difference was used for the continuous data. Standard deviations were calculated using the methodology described by Hozoand associates if continuous data was presented as means and range [26]. All the outcomes were reported with 95% confidence intervals (95% CI). The chi-square test and I<sup>2</sup> value were used to identify the heterogeneity among studies. Pooled estimates were firstly calculated with the fixed-effect model. However, if significant heterogeneity (I<sup>2</sup> > 50%) was detected and it could not be dissolved by subgroup analysis, the random-effect model was used. The pooled effects were determined by the z test and p < 0.05 was considered statistically significant. Moreover, a sensitivity analysis was performed by pooling only RCTs or studies in which flexible ureteroscopy was not mentioned as an intraoperative auxiliary procedure during rigid URSL.

### Results

### Characteristics of eligible studies

Ten studies, involving 417 patients who underwent rigid URSL and 420 underwent PCNL, were included in our meta-analysis. Fig 1 shows the procedure of literature search and study selection. The studies consisted of five RCTs [12–16], one prospective [19] and four retrospective cohort studies [17,18,20,21]. Basic characteristics, such as age, sex ratio, stone size and stone side, were described comparable between rigid URSL and PCNL group in each study and the data was presented in Table 1. Some studies also reported other basic characteristics





Deference week		uuy.		stuay	surgical		sample	Age	vex		Storie side	Postoperative
Deleterice, year indu	on de	sign	LOE	quality*	technique	Type of facility	size	(year)	(M/F)	Stone burden	(left/right)	SWL
								(M±SD)				
Sun et al, 2008 Chir	na	CT	2		URSL	Rigid ureteroscope	47	39.6±7.3	31/16	14.6±1.8 mm	Q	No
					mini-PCNL	Rigid ureteroscope	44	40.4±8.4	30/14	14.7±2.0 mm	Q	
Basiri et al, 2008 Ira	E.	CT	2		URSL	Semi-rigid ureteroscope	50	39±15	33/17	17.8±2.4 mm	26/22	No
					PCNL	Rigid nephroscope	50	48±13	32/18	20.3±3.3 mm	31/19	
Liu et al, 2013 Chir	na	СT	2		URSL	Rigid ureteroscope	45	43.41±10.17	25/20	148.13±27.52mm <sup>3</sup>	23/22	Yes
					mini-PCNL	Rigid ureteroscope	45	46.35±0.31	23/22	146.85±30.36mm <sup>3</sup>	24/21	
Gu et al, 2013 Chir	na	CT	2		URSL	Semi-rigid, flexible ureteroscope	29	44.22± 13.0	17/12	16.23(15-25)mm	12/17	Yes
					mini-PCNL	Rigid ureteroscope	30	42.5±10.1	17/13	17.27(15–25)mm	16/14	
Qi et al, 2014 Chir	na	СT	2		URSL	Semi-rigid, flexible ureteroscope	52	42.5±10.3	31/21	19.8±4.3mm	30/22	Yes
					PCNL	Rigid nephroscope	52	41.1±12.4	30/22	20.3±3.6mm	27/25	
Maheshwari et al, Ind	lia	SS	e	6/2	URSL	Rigid ureteroscope	20	QN	14/6	QN	Q	Yes
1999					PCNL	Rigid ureteroscope,	23	QN	15/8	QN	Q	
Juan et al, 2008 Chir	na (	SC	e	8/9	URSL	Semi-rigid ureteroscope	31	48.9 ± 12.5	23/8	18.6±6.3mm	18/13	N
					PCNL	Rigid nephroscope, semi-rigid ureteroscope	22	48.2±11.2	16/6	20.1 ± 5.4mm	13/9	
Li et al, 2013 Chir	na	SC	e	6/6	URSL	Semi-rigid, flexible ureteroscope	91	45.35±12.51	44/47	20.61±4.26 mm	45/48**	No
					PCNL	Rigid nephroscope	83	44.12±11.56	46/37	20.00±4.44mm	39/44	
Zhu et al, 2014 Chir	na	SS	e	8/9	URSL	Semi-rigid ureteroscope	22	49.6±7.1	14/8	1.2±0.8cm	12/10	Yes
					PCNL	Rigid nephroscope	30	51.9±8.4	18/12	1.4±0.7cm	17/13	
Bozkurt et al, Turk	(ey (	SS	e	8/9	URSL	Semi-rigid, flexible ureteroscope	41	42.1 ± 14.9	27/18#	261 ± 47mm <sup>2</sup>	QN	No
2015					PCNL	Rigid nephroscope	45	44.7 ± 16.3	22/19#	$314 \pm 64 \text{mm}^2$	QN	

Table 1. Characteristics and methodological quality of included studies.

lithotripsy ND: not demonstrated.

\*The quality of the non-randomized controlled trials (nRCTs) was assessed using the Newcastle-Ottawa Scale.

\*\* Totally 91 patients were included in the URSL group, the authors didn't mention bilateral stones and they might report a wrong ratio of stone side.

# The author might report the gender ratio inversely in two groups.





doi:10.1371/journal.pone.0171478.g002

that might make a difference in the clinical outcomes: preoperative renal function including serum creatinine (SCr), blood urea nitrogen (BUN) or golomeruar filtration rate (GFR), failed SWL history, and degree of hydronephrosis [14,15,17,19,20]. All the data was also comparable between the two groups according to each study.

### Quality of the studies

As shown in Table 1, all RCTs were rated Level 2 and cohort studies were rated Level 3.Fourcohort studies [17–20] scored  $\geq$ 8 stars were considered to be of high quality while one study [21] was scored 7 stars. Fig 2A showed that all of the RCTs described suggested randomization. Three studies [12,13,16] failed to report details about allocation concealment. It was quite difficult to perform blinding of participants or personnel in surgical treatment, so a high risk of bias was judged in this part for each study. The blinding outcome measurement was judged to low risk of bias because the outcomes were unlikely to be influenced by lack of blinding. One study [13] had a high risk of selective reporting bias for lack of detailed explanation for some important outcomes. All studies had low risk of other biases. Finally, two RCTs [14,15] were judged to be of high methodological quality while the other three RCTs [12,13,16] were of low quality.

### **Publication bias**

The publication bias was explored via funnel plots. As showed in Fig 2B, the funnel plot of operation time included all studies and seemed asymmetric, which might be explained by publication bias and heterogeneity.

### Operation time

Pooling the data from ten studies [12–21] that assessed operation time showed less time in rigid URSL group than in PCNL group(WMD, -23.66min; 95%CI, -45.00 to -2.32; p = 0.03; Fig 3A).

### Hospital stay

Meta-analysis of nine studies [12-20] by a random effects model showed that the rigid URSL group charged with a shorter hospital stay of 2.76d than the PCNL group (WMD, -2.76d; 95% CI, -3.51 to -2.02; p< 0.00001; Fig 3B).

# The 3<sup>rd</sup>-day stone-free rate

Pooling the data from five studies [12,13,15,16,21] demonstrated that the 3<sup>rd</sup>-day stone-free rate of rigid URSL group was significantly lower than that of PCNL group (RR, 0.73; 95%CI, 0.66 to 0.82; p < 0.00001; Fig 4A).

### The 1<sup>st</sup>-month stone-free rate

In terms of the 1<sup>st</sup>-month stone-free rate, the studies were divided into two subgroups according to whether the patients with residual stones received a postoperative auxiliary SWL within

#### A.Operation time

	Rig	jid URS	L	F	PCNL			Mean Difference		Mea	n Differe	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Ra	ndom, 9	5% CI	
Basiri 2008	42.7	17.9	50	93.6	28.9	50	10.1%	-50.90 [-60.32, -41.48]		-	_		
Bozkurt 2015	92	32.5	41	107	39.5	45	9.8%	-15.00 [-30.24, 0.24]			•		
Gu 2013	66.7	13.75	29	96.2	21.25	30	10.1%	-29.50 [-38.60, -20.40]		-			
Juan 2008	88.6	28.5	31	115.4	49.5	22	9.2%	-26.80 [-49.79, -3.81]					
Li 2013	63.56	16.38	83	108.76	19.36	80	10.2%	-45.20 [-50.72, -39.68]					
Liu 2013	60.14	18.72	45	53.82	19.18	45	10.1%	6.32 [-1.51, 14.15]			-		
Maheshwari 1999	61.25	16.25	20	110	27.5	23	9.9%	-48.75 [-62.06, -35.44]		-			
Qi 2014	66.7	15.3	52	38.5	8.2	52	10.2%	28.20 [23.48, 32.92]				-	
Sun 2008	30.6	7.8	44	75.4	11.8	43	10.2%	-44.80 [-49.01, -40.59]					
Zhu 2014	51.6	15.7	22	62.6	18.3	30	10.1%	-11.00 [-20.27, -1.73]		-	-		
			447			420	100.0%	22 66 [ 46 00 2 22]					
Total (95% CI)			417			420	100.0%	-23.00 [-45.00, -2.32]	- 1				
Heterogeneity: Tau <sup>2</sup> =	1152.20	; Chi² =	725.03	8, df = 9 (	P < 0.0	0001);	l² = 99%		-100	-50	ó	50	100
Test for overall effect:	Z = 2.17	(P = 0.	03)						100	Rigid UR	SI PCI	NI.	100

#### **B.Hospital stay**

	Rig	id UR	SL	F	PCNL			Mean Difference		Mean D	ifference	3	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Rand	<u>om, 95%</u>	CI	
Basiri 2008	0.53	0.12	50	4.4	1.4	50	11.7%	-3.87 [-4.26, -3.48]					
Bozkurt 2015	1.8	1	41	4.3	1.6	45	11.3%	-2.50 [-3.06, -1.94]		-			
Gu 2013	1.9	1.3	29	4.6	1.8	30	10.6%	-2.70 [-3.50, -1.90]	_	•			
Juan 2008	1.9	1.1	31	4.7	2	22	10.2%	-2.80 [-3.72, -1.88]		-			
Li 2013	2.49	1.23	83	5.36	1.98	80	11.5%	-2.87 [-3.38, -2.36]	-				
Liu 2013	5.18	0.68	45	6.76	3.08	45	10.2%	-1.58 [-2.50, -0.66]					
Qi 2014	1.7	1.3	52	4.6	2.1	52	11.0%	-2.90 [-3.57, -2.23]		•			
Sun 2008	2.1	0.4	44	6.3	0.5	43	12.0%	-4.20 [-4.39, -4.01]	-				
Zhu 2014	3.2	0.9	22	4.4	1.2	30	11.3%	-1.20 [-1.77, -0.63]		-			
Total (95% Cl)			397			397	100.0%	-2.76 [-3.51, -2.02]					
Heterogeneity: Tau <sup>2</sup> =	1.18; Cł	ni² = 16	60.85, c	df = 8 (F	o.0 > 9	0001);	² = 95%	-			-		
Test for overall effect:	Z = 7.29	(P < (	0.00001	1)					-4	-2 Rigid URSL	PCNL	Z	4

Fig 3. Forest plots of (A) operation time, (B) hospital stay.

### A.The 3rd-day stone-free rate

	Rigid U	RSL	PCN	L		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Basiri 2008	28	50	32	50	17.2%	0.88 [0.63, 1.21]	
Liu 2013	23	45	41	45	22.0%	0.56 [0.42, 0.76]	<b>_</b>
Maheshwari 1999	11	20	23	23	11.8%	0.56 [0.38, 0.83]	
Qi 2014	39	52	50	52	26.8%	0.78 [0.66, 0.92]	
Sun 2008	35	44	41	43	22.2%	0.83 [0.71, 0.98]	
Total (95% CI)		211		213	100.0%	0.73 [0.66, 0.82]	•
Total events	136		187				
Heterogeneity: $Chi^2 = 8$	3.92. df = 4	4(P = 0)	.06): $I^2 = \frac{1}{2}$	55%		-	
Test for overall effect:	Z = 5.48 (F	P < 0.00	001)				0.5 0.7 1 1.5 2
			,				RIGIO URSL PONL
B.The 1st-month st	one-free	rate					
	Riaid U	RSL	PCN	L		Risk Ratio	Risk Ratio
Study or Subaroup	Events	Total	Events	Total	Weight	M-H. Fixed. 95% CI	M-H. Fixed, 95% Cl
1 With postoperative	auxiliarv	SWL					
Gu 2013	26	29	30	30	8.9%	0 90 [0 78 1 03]	
Juan 2008	18	31	21	22	7.3%	0.61 [0.44, 0.83]	
Liu 2013	37	45	44	45	13.0%	0.84 [0.73, 0.97]	<b>_</b> _
Zhu 2014	17	22	30	30	7.7%	0.77 [0.61 0.98]	
Subtotal (95% CI)		127	00	127	36.9%	0.79 [0.72, 0.87]	$\bullet$
Total events	98		125				
Heterogeneity: $Chi^2 = f$	348 df = 3	B(P=0)	$(120)^{12} = 10^{12}$	54%			
Test for overall effect:	7 = 4 71 (F)		00), 1 – 1	J <del>-1</del> 70			
	<u> </u>	× 0.00	001)				
2 Without Postoperat	ive auxilia	ary SWI	L				
Basiri 2008	38	50	43	50	12.8%	0.88 [0.73, 1.07]	
Bozkurt 2015	34	41	44	45	12.4%	0.85 [0.73, 0.98]	
Li 2013	69	91	80	83	24.8%	0.79 [0.70, 0.89]	_ <b>_</b>
Sun 2008	38	44	43	43	13.0%	0.87 [0.76, 0.98]	
Subtotal (95% CI)		226		221	63.1%	0.83 [0.78, 0.90]	$\bullet$
Total events	179		210				
Heterogeneity: Chi <sup>2</sup> = 1	1.60. df = 3	3(P = 0)	66): $ ^2 = 0$	0%			
Test for overall effect:	Z = 4.85 (F	> < 0.00	001)				
Total (95% CI)		353		348	100.0%	0.82 [0.77, 0.87]	◆
Total events	277		335				
Heterogeneity: Chi <sup>2</sup> = 7	7.49, df = 7	7 (P = 0	.38); l² = (	6%		-	
Test for overall effect:	Z = 6.70 (F	> < 0.00	001)				
Test for subgroup diffe	rences: Cl	ni² = 0.6	4, df = 1	(P = 0.4	42), l <sup>2</sup> = 0 <sup>4</sup>	%	RIGIU UROL FUNL

Fig 4. Forest plots of (A) The 3<sup>rd</sup>-day stone-free rate, (B) The 1<sup>st</sup>-month stone-free rate with and without postoperative auxiliary SWL.

doi:10.1371/journal.pone.0171478.g004

the 1st month. Meta-analysis of four studies [14,16,18,20] referring to postoperative auxiliary SWL showed that the 1<sup>st</sup>-month stone-free rate of rigid URSL group was lower than that of PCNL group (RR, 0.79; 95%CI, 0.72 to 0.87; p < 0.00001; Fig 4B). "Without postoperative auxiliary SWL" subgroup consisted of four studies [13,15,17,19] and the analysis also revealed that the 1<sup>st</sup>-month stone-free rate of rigid URSL group was lower than that of PCNL group (RR, 0.83; 95%CI, 0.78 to 0.90; p < 0.00001; Fig 4B). Total effect of the two subgroups indicated lower 1<sup>st</sup>-month stone-free rate in rigid URSL group than in PCNL group (RR, 0.82; 95%CI, 0.77 to 0.87; p < 0.00001; Fig 4B).

## Intraoperative complications

Patients who underwent rigid URSL, rather than PCNL, were associated with a higher risk of conversion to other surgical procedures (RR, 4.28; 95%CI, 1.93 to 9.46; p = 0.0003; Fig 5) [12,14,15,17–21], migration (RR, 28.49; 95%CI, 9.12 to 89.00; p < 0.00001; Fig 5) [12,14,17–20] and ureteral perforation (RR, 6.06; 95%CI, 1.80 to 20.44; p = 0.004; Fig 5) [12,14–16,19,21].

# Postoperative complications

There was no significant difference between rigid URSL and PCNL when it came to pain (RR, 0.71; 95%CI, 0.44 to 1.15; p = 0.17; Fig 6) [14,20], embolization (RR, 0.33; 95%CI, 0.05 to 2.04;

	Rigid UI	RSL	PCNL	_		<b>Risk Ratio</b>		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
1 Conversion								
Bozkurt 2015	3	41	0	45	6.7%	7.67 [0.41, 144.08]		
Gu 2013	3	29	0	30	6.9%	7.23 [0.39, 134.16]		*
Juan 2008	1	31	0	22	8.2%	2.16 [0.09, 50.59]		
Li 2013	8	91	3	83	44.1%	2.43 [0.67, 8.86]		+=
Maheshwari 1999	1	20	0	23	6.6%	3.43 [0.15, 79.74]		· · · ·
Qi 2014	3	52	0	52	7.0%	7.00 [0.37, 132.23]		• • • • • • • • • • • • • • • • • • •
Sun 2008	3	47	1	44	14.5%	2.81 [0.30, 26.00]		
Zhu 2014	5	22	0	30	6.0%	14.83 [0.86, 254.87]		
Subtotal (95% CI)		333		329	100.0%	4.28 [1.93, 9.46]		
Total events	27		4					
Heterogeneity: Chi <sup>2</sup> = 2	.19, df = 7	(P = 0	.95); l² = 0	1%				
Test for overall effect: Z	z = 3.59 (F	P = 0.00	03)					
2 Migration								_
Bozkurt 2015	15	41	0	45	15.9%	33.95 [2.10, 549.98]		
Gu 2013	9	29	0	30	16.4%	19.63 [1.19, 322.59]		
Juan 2008	8	31	0	22	19.4%	12.22 [0.74, 201.21]		
Li 2013	24	91	0	83	17.4%	44.74 [2.76, 724.25]		
Qi 2014	20	52	0	52	16.7%	41.00 [2.54, 660.52]		
Zhu 2014	7	22	0	30	14.2%	20.22 [1.22, 336.29]		
Subtotal (95% CI)		266		262	100.0%	28.49 [9.12, 89.00]		-
Total events	83		0					
Heterogeneity: Chi <sup>2</sup> = 0	.66, df = 5	(P = 0	.99); I² = 0	1%				
Test for overall effect: Z	Z = 5.76 (F	<b>c</b> < 0.00	001)					
2 Urotoral parforation								
	1	20	0	20	16 50/	2 10 10 12 72 141		
Gu 2013	0	29	0	00	17 10/			
LI 2013	0	00	0	45	16 90/	2 00 10 12 71 741		
Liu 2013 Mahaahwari 1000	1	40	0	40	10.0%	5.00 [0.13, 71.74]		
	2	20	0	23	16 00/	5.71 [0.29, 112.43]		
QI 2014	2	52	0	12	17.0%	2.00 [0.25, 101.06]		
Subtotal (95% CI)		44 272	0	43 272	100.0%	2.93 [0.12, 70.06]		
Subtotal (95 % Cl)	45	215	0	215	100.076	0.00 [1.00, 20.44]		-
		(D - 0		0/				
Test for every offect.	105, at = 5	(P = 0)	.90); 1 <sup>-</sup> = 0	170				
rest for overall effect: 2	L = 2.91 (F	r = 0.00	4)					
							L	
							0.001	0.1 1 10 1000
								Rigid URSL PCNL

### Fig 5. Forest plots of conversion, migration and ureteral perforation.

	Rigid U	RSL	PCNI	L		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
1 Fever							
Bozkurt 2015	5	41	6	45	12.3%	0.91 [0.30, 2.77]	<b>_</b>
Gu 2013	5	29	17	30	35.8%	0.30 [0.13, 0.72]	
Juan 2008	2	31	6	22	15.1%	0.24 [0.05, 1.06]	
Li 2013	8	83	9	80	19.7%	0.86 [0.35, 2.11]	
Liu 2013	2	45	3	45	6.4%	0.67 [0.12, 3.80]	
Qi 2014	8	52	5	52	10.7%	1.60 [0.56, 4.57]	
Subtotal (95% CI)		281		274	100.0%	0.64 [0.42, 0.97]	$\bullet$
Total events	30		46				
Heterogeneity: Chi <sup>2</sup> = 8	3.31, df =	5 (P = 0	.14); l² = 4	40%			
Test for overall effect: 2	Z = 2.08 (I	P = 0.04	)				
0.7							
2 Transfusion	•			45	44.00/	0.07 10.00 0.701	
Bozkurt 2015	0	41	1	45	14.0%	0.37 [0.02, 8.72]	
Juan 2008	0	31	2	22	28.4%	0.14 [0.01, 2.85]	
Li 2013	0	83	3	80	34.8%	0.14 [0.01, 2.63]	
Maneshwari 1999	0	20	2	23	22.8%	0.23 [0.01, 4.50]	
Subtotal (95% CI)	0	175	0	170	100.0%	0.19 [0.04, 0.65]	
I otal events		2 /D – 0	07).12 - (	20/			
Test for overall effect:	7 – 2 17 (I	3(P = 0)	.97); I <sup>2</sup> = (	J%			
Test for overall effect. 2	2 - 2.17 (1	0.03	)				
3 Embolization							
Bozkurt 2015	0	41	1	45	31.5%	0.37 [0.02, 8,72]	
Li 2013	0	91	1	83	34.5%	0.30 [0.01, 7.37]	<b>_</b>
Sun 2008	0	47	1	44	34.0%	0.31 [0.01, 7.47]	
Subtotal (95% CI)	-	179		172	100.0%	0.33 [0.05, 2.04]	
Total events	0		3				
Heterogeneity: Chi <sup>2</sup> = 0	0.01, df = 2	2 (P = 1	.00); l <sup>2</sup> = (	0%			
Test for overall effect: 2	Z = 1.20 (I	P = 0.23	)				
4 Hematuria							
Gu 2013	5	29	15	30	23.4%	0.34 [0.14, 0.83]	
Juan 2008	7	31	12	22	22.3%	0.41 [0.19, 0.88]	
Li 2013	9	83	14	80	22.6%	0.62 [0.28, 1.35]	
Qi 2014	4	52	20	52	31.7%	0.20 [0.07, 0.54]	
Subtotal (95% CI)		195		184	100.0%	0.38 [0.25, 0.57]	•
Total events	25		61				
Heterogeneity: Chi <sup>2</sup> = 3	3.20, at = 3	3(P = 0)	$(36); I^2 = 0$	5%			
Test for overall effect. 2	2 – 4.59 (1	- < 0.00	001)				
5 Pain							
Gu 2013	12	29	15	30	61 2%	0 83 [0 47 1 45]	
Juan 2008	6	31	8	22	38.8%	0.53 [0.21, 1.32]	
Subtotal (95% CI)	Ŭ	60	0	52	100.0%	0.71 [0.44, 1.15]	•
Total events	18		23				
Heterogeneity: Chi <sup>2</sup> = 0	).67, df =	1 (P = 0	.41); l <sup>2</sup> = (	0%			
Test for overall effect: 2	Z = 1.38 (I	P = 0.17	)				
6 Ureterostenosis							_
Li 2013	2	83	0	80	33.7%	4.82 [0.24, 98.89]	
Liu 2013	2	45	1	45	66.3%	2.00 [0.19, 21.28]	
Subtotal (95% CI)		128		125	100.0%	2.95 [0.47, 18.46]	
Total events	4	9 (55C) 10	1				
Heterogeneity: Chi <sup>2</sup> = 0	).21, df =	1 (P = 0	.65); l² = (	0%			
Test for overall effect: 2	z = 1.16 (l	- = 0.25	)				
							· · · · · · · · · · · · · · · · · · ·
							0.001 0.1 1 10 1000
							Rigid URSL PCNL

Fig 6. Forest plots of fever, transfusion, embolization, hematuria, pain, and ureterostenosis.

p = 0.23; Fig 6) [15,17,19] and ureterostenosis (RR, 2.95; 95%CI, 0.47 to 18.46; p = 0.25; Fig 6) [16,19]. Compared to patients underwent PCNL, those underwent rigid URSL were associated with a lower risk of fever (RR, 0.64; 95%CI, 0.42 to 0.97; p = 0.04; Fig 6) [12,14,16,17,19,20], transfusion (RR, 0.19; 95%CI, 0.04 to 0.85; p = 0.03; Fig 6) [17,19–21] and hematuria (RR, 0.38; 95%CI, 0.25 to 0.57; p < 0.0001; Fig 6) [12,14,19,20].

### Sensitivity analysis

Table 2 showed the results of sensitivity analysis. When only the RCTs [12–16] were included, most of the outcomes including hospital stay, 3<sup>rd</sup>-day stone free rate, 1<sup>st</sup>-month stone free rate, and the incidence of conversion to other surgical procedures, migration, ureteral perforation and postoperative hematuria were stable. However, significant difference in operation time and fever between the two groups could not be observed again. Despite this, the tendency remained the same. When studies [12,14,17,19] mentioning flexible URSL as intraoperative auxiliary procedure were excluded, there came similar results and significant difference in transfusion was no longer detectable.

### Discussion

Large proximal ureteral stones can cause urinary obstruction and some of them are impacted, which prevents the passage of a guidewire or ureteral catheter and enhances the surgical

		Sample size	Те	st for	Т	est for		
Items	Studies	URSL/ PCNL	Heter	ogeneity	over	all effect	RR / WMD	Favor
			l <sup>2</sup>	P*	Z	P*	95% Cl	
Analysis of RCTs							1	
Operation time(min)	[12–16]	220/220	99%	<0.001	1.02	0.31**	-18.08[-52.96,16.80]	-
Hospital stay(d)	[12-16]	220/220	92%	<0.001	8.02	<0.001	-3.14 [-3.91, -2.37]	URSL
3-day SFR	[12,13,15,16]	191/190	51%	0.11	4.74	<0.001	0.76 [0.68, 0.85]	PCNL
1-month SFR	[13–16]	139/160	0%	0.93	3.55	0.0004	0.87 [0.81, 0.94]	PCNL
Conversion	[12,14,15]	128/126	0%	0.83	2.09	0.04	4.92 [1.11, 21.86]	PCNL
Migration	[12,14]	81/82	0%	0.71	3.39	0.007	30.40 [4.23, 218.62]	PCNL
Ureteral perforation	[12,14–16]	170/170	0%	0.99	1.58	0.11	3.51 [0.74, 16.65]	PCNL
Fever	[12,14,16]	126/127	65%	0.06	1.67	0.09**	0.61 [0.34, 1.09]	-
Hematuria	[12,14]	81/82	0%	0.42	3.98	<0.001	0.26 [0.14, 0.51]	URSL
Analysis of studies wi	thout using flexible uret	eroscope						-
Operation time(min)	[13,15,16,18,20,21]	212/213	97%	<0.001	2.76	0.006	-29.28 [-50.05, -8.50]	URSL
Hospital stay(d)	[13,15,16,18,20]	192/190	97%	<0.001	4.67	<0.001	-2.77 [-3.93, -1.61]	URSL
3-day SFR	[13,15,16,21]	159/161	66%	0.03	4.68	<0.001	0.72 [0.62, 0.82]	PCNL
1-month SFR	[13,15,16,18,20]	192/190	24%	0.26	4.83	<0.001	0.82 [0.75, 0.89]	PCNL
Conversion	[15,18,20,21]	120/119	0%	0.77	2.37	0.02	4.81 [1.31, 17.69]	PCNL
Migration	[18,20]	53/52	0%	0.8	2.73	0.006	15.60 [2.18, 111.80]	PCNL
Ureteral perforation	[15,16,21]	109/111	0%	0.94	1.49	0.14	3.84 [0.65, 22.60]	PCNL
Fever	[16,21]	76/67	0%	0.38	1.79	0.07***	0.37 [0.12, 1.10]	-
Transfusion	[20,21]	51/45	0%	0.83	1.6	0.11***	0.18 [0.02, 1.48]	-

#### Table 2. Results of sensitivity analysis.

URSL: (rigid) ureteroscopic lithotripsy PCNL: percutaneous nephrolithotomy SFR: stone-free rate.

RR: relative risk WMD: weighted mean difference CI: confidence interval.

\* P<0.05 was considered statistically significant

\*\* Originally significant before nRCTs were excluded.

\*\*\*Originally significant before studies using flexible ureteroscope were excluded.

challenge for urologists [27]. Progressive back pressure on the kidney caused by long term obstruction may ultimately lead to significant cortical atrophy and impairment of renal function. Moreover, secondary nephropyosis may be life-threatening [28]. The development of more minimally invasive techniques for treating proximal ureteral stones, such as URSL and PCNL, has largely replaced open surgery.

URSL was first recorded in 1912, and then rapid development of smaller rigid ureteroscopes, reliable laser technology, digital imaging system and flexible instruments has further expanded the indications for its use [29]. Since 1976 Fernström and Johansson firstly introduced PCNL into routine clinical practice, it has been recommended as the first-line treatment of large (>2cm), multiple and inferior calyx renal stones [4]. Although progressive advances in percutaneous approach have been achieved with the advent of mini-, ultramini- and micro-PCNL, PCNL is still associated with a considerable overall complication rate, including perioperative bleeding, fever or sepsis, adjacent organ injury and so on [30,31].

This meta-analysis is the first systematic review comparing the outcomes of rigid URSL and PCNL in treating large proximal ureteral stones. Ten studies (837 patients) were included. No significant difference was observed between the two groups in terms of baseline characteristics, which promised reasonable comparisons.

A higher risk of conversion to another surgical procedures, migration and ureteral perforation was observed in URSL. Upward migration of ureteral stones or big fragments is the main reason for failure in rigid URSL and the reported incidence ranges from 28% to 60% [32], which is generally caused by the increment of irrigation fluid pressure to gain a clear vision and the back-pressure effect of lithotripsy equipment. Although some studies used an antiretropulsion device such as retrieval basket during rigid URSL, the large impacted stones did not allow additional space for passing the wire of the device and the sever dilation of upper urinary tract sometimes seemed larger than the device [12,14,17]. Moreover, the edematous and inflammatory mucosa or fibroepithelial polyp may result in impede visualization of the stones, which makes it difficult to perform the lithotripsy [33,34]. Sometimes a tortuous ureter or unusual angulation of the ureter also makes it difficult to reach the stones. In these cases, urologists would choose to make conversion to PCNL, laparoscopic or open ureterolithotomy. Ureteral perforation is a serious complication during rigid URSL but most of these perforations are minor and can be managed by ureteral stents [35]. Some severe cases may need conversion to an open ureterolithotomy for further ureteral repair. PCNL is superior in avoiding migration because it is performed via an antegrade tract, which allows it acting as an effective anti-reputation device.

The 3rd-day stone-free rate of PCNL was found to be higher than that of rigid URSL. Upward migrations of ureteral stones or big fragments often lead to incomplete rigid URSL. If a migration happened, an auxiliary procedure such as flexible URSL or SWL would often be needed. Flexible URSL was performed in the same session while SWL was always performed 1-week latter or after the first follow-up. Although flexible ureteroscopy improved the efficiency of URSL, it should be indicated that flexible ureteroscope is still not available in many hospitals in developing countries due to high cost for the equipment. We didn't conduct a subgroup analysis because there was only one study in this part performing flexible URSL as an auxiliary procedure. Postoperative SWL as an auxiliary procedure was found in five studies [12,14,16,18,21], both the overall and "With postoperative auxiliary SWL" subgroup 1st-month stone-free rate were found lower in rigid URSL, let alone the "Without postoperative auxiliary SWL" subgroup. There might be several superiorities ensure the high efficiency in stone clearance for PCNL. Since most patients with large impacted proximal stones develop hydronephrosis, allowing easier and safer puncture and more space for the nephroscope. Another advantage of PCNL is that an associated renal stones can be removed simultaneously. What's more, if access to stones

which locate below the upper border of the fourth lumbar vertebra is difficult for nephroscope, percutaneous antegrade ureteroscopy through the nephroscope sheath will be a good alternative modality because the rigid ureteroscope can reach the entire upper ureter [36].

We found that it took less time to perform rigid URSL than PCNL. It should be indicated that most studies didn't state the definition of operation time clearly and each study might calculate the operation time in different criteria, which was also the most important reason for high heterogeneity. Moreover, operation time mainly depends on patient characteristics and surgeon's experience. The shortest and longest operation time for rigid URSL in included studies was  $30.6\pm7.8$ min [15] and  $92.0\pm32.5$ min [17] respectively, while  $38.5\pm8.2$ min [12] and  $115.4\pm49.5$ min [20] for PCNL, which showed a great difference.

Rigid URSL yielded significantly shorter hospitalization duration than PCNL. Currently, patients undergoing surgery expect to return to work and to daily activities soon. However, more invasive technique requires more time to make sure that no sever postoperative complications will happen. So after PCNL, patients are often required to lie in bed and limit their activities for several days to reduce the risk of bleeding.

In addition, PCNL was associated with higher risk of transfusion and hematuria than rigid URSL. This result is consistent with the fact that bleeding is generally common in PCNL, which may require transfusion. Actually, a systematic review has reported that the overall transfusion rate is about 7%, indicating the rare requirement of transfusion for PCNL [10]. If conservative measures fail, 0–1.5% cases require selective embolization [11]. Our meta-analysis showed no statistically significant difference of embolization between two groups and ensured the safety of PCNL.

Overall, we found no statistically significant difference in pain, despite the fact that PCNL is more invasive. Although ureteral perforation was more common in rigid URSL according our analysis, most of these perforations were minor and could be managed by ureteral stents. Thus it might be the reason for no statistically significant difference of ureterostenosis. However, only two studies [16,19] referred to ureterostenosis and the follow-up time was not all the same, so more studies should be conducted to prove the reality of this outcome.

There are several limitations in our meta-analysis. Firstly, we defined "large" as stones with a size > 10mm according to EAU guideline [4] but eight studies [12-14,16,17,19-21] in our analysis defined "large" as stones > 15mm. Although the results were the same when we only analyzed the eight studies (data not shown), more studies completely according with our definition were expected to confirm the stability of our analysis. Secondly, the sample size of each study was small and only 837 patients were included. After that, there were only five RCTs in this analysis. Thirdly, although AUA guideline has recommended that flexible ureteroscope should be available when performing URSL for proximal ureteral stones [1], we only focused on rigid URSL in this analysis, which may not represent the latest tendency for ureteroscopic lithotripsy. Fourthly, there existed significant heterogeneities when assessing continuous data such as operation time and hospital stay. Lastly, the funnel plot of operation time, which included all studies, indicated that there might be a publication bias for the included studies.

### Conclusion

In conclusion, our meta-analysis shows that both PCNL and rigid URSL are safe for patients with large proximal ureteral stones, despite the fact that PCNL is associated with a higher risk of transfusion and rigid URSL gets more ureteral perforation. PCNL seems more likely to be successful and is also superior to URSL in stone clearance, which is a very important index to evaluate the efficiency of a surgical technique. More clinical trials in the future need to be conducted to confirm the outcomes of our meta-analysis.

### Supporting information

**S1 File. PRISMA 2009 checklist.** (DOC)

### **Author Contributions**

Conceptualization: QW JG SW.

Formal analysis: QW JG.

Investigation: QW JG HH YL JZ BQ YW ZZ.

Methodology: QW JG.

Project administration: QW JG.

Supervision: SW.

Validation: QW JG HH YL JZ BQ YW ZZ.

Visualization: QW JG.

Writing - original draft: QW JG.

Writing - review & editing: HH YL JZ BQ YW ZZ.

#### References

- 1. Dean A, Amy K, Nicole L. M, Manoj M, Hassan M, Caleb P. N, et al. Surgical management of stones: American Urological Association / Endourological Society Guideline. Available from: http://www.auanet. org/education/guidelines/surgical-management-of-stones. Accessed December 15, 2016.
- Preminger GM, Tiselius H, Assimos DG, Alken P, Buck C, Gallucci M, et al. 2007 Guideline for the management of ureteral calculi. J Urol. 2007; 178:2418–2434. doi: 10.1016/j.juro.2007.09.107 PMID: 17993340
- Wu CF, She JJ, Lin WY, Lin CL, Chen CS. Comparison between extracorporeal shock wave lithotripsy and semirigid ureterorenoscope with holmium: YAG laser lithotripsy for treating large proximal ureteral stones. J Urol. 2004; 172: 1899–1902. PMID: 15540749
- 4. Türk C, Knoll T, Petrik A, Sarica K, Skolarikos A, Straub M, et al. Guidelines on urolithiasis. EAU. 2016. Available at: http://uroweb.org/guideline/urolithiasis/. Accessed December 15, 2016.
- Salem HK. A prospective randomized study comparing shock wave lithotripsy and semirigid ureteroscopy for the management of proximal ureteral calculi. Urology. 2009; 74: 1216–1221. doi: 10.1016/j. urology.2009.06.076 PMID: 19815264
- Lam JS, Greene TD, Gupta M. Treatment of proximal ureteral calculi: holmium: YAG laser ureterolithotripsy versus extracorporeal shock wave lithotripsy. J Urol. 2002; 167: 1972–1976. PMID: 11956420
- Juan YS, Li CC, Shen JT, Huang CH, Chuang SM, Wang CJ, et al. Percutaneous nephrostomy for removal of large impacted upper ureteral stones. Kaohsiung J Med Sci. 2007; 23: 412–416. doi: 10. 1016/S0257-5655(07)70005-6 PMID: 17666308
- Goel R, Aron M, Kesarwani PK, Dogra PN, Hemal AK, Gupta NP, et al. Percutaneous antegrade removal of impacted upper-ureteral calculi: still the treatment of choice in developing countries. J Endourol. 2015; 19: 54–57.
- Long Q, Guo J, Xu Z, Yang Y, Wang H, Zhu Y, et al. Experience of mini-percutaneous nephrolithotomy in the treatment of large impacted proximal ureteral stones. Urol Int. 2013; 90: 384–388. doi: 10.1159/ 000343668 PMID: 23635397
- Kallidonis P, Panagopoulos V, Kyriazis I, Liatsikos E. Complications of percutaneous nephrolithotomy: classification, management, and prevention. Curr Opin Urol. 2016; 26: 88–94. doi: 10.1097/MOU. 0000000000232 PMID: 26555687
- 11. Seitz C, Desai M, Häcker A, Hakenberg OW, Liatsikos E, Nagele U, et al. Incidence, prevention, and management of complications following percutaneous nephrolitholapaxy. Eur Urol. 2012; 61: 146–58. doi: 10.1016/j.eururo.2011.09.016 PMID: 21978422

- Qi SY, Li YN, Liu X, Zhang CW, Zhang HT, Zhang ZH, et al. Clinical efficacy, safety, and costs of percutaneous occlusive balloon catheter-assisted ureteroscopic lithotripsy for large impacted proximal ureteral calculi: a prospective, randomized study. J Endourol. 2014; 28: 1064–1070. doi: 10.1089/end. 2014.0167 PMID: 24786613
- 13. Basiri A, Simforoosh N, Ziaee A, Shayaninasab H, Moghaddam S, Zare S. Retrograde, antegrade, and laparoscopic approaches for the management of large, proximal ureteral stones: a randomized clinical trial. J Endourol. 2008; 22: 2677–2680. doi: 10.1089/end.2008.0095 PMID: 19025388
- Gu XJ, Lu JL, Xu Y. Treatment of large impacted proximal ureteral stones: randomized comparison of minimally invasive percutaneous antegrade ureterolithotripsy versus retrograde ureterolithotripsy. World J Urol. 2013; 31: 1605–1610. doi: 10.1007/s00345-013-1026-2 PMID: 23334470
- Sun XW, Xia SJ, Lu J, Liu HT, Han BM, Li WG. Treatment of large impacted proximal ureteral stones: randomized comparison of percutaneous antegrade ureterolithotripsy versus retrograde ureterolithotripsy. J Endourol. 2008; 22: 913–917. doi: 10.1089/end.2007.0230 PMID: 18429682
- Liu YH, Zhou ZY, Xia A, Dai HT, Guo LJ, Zheng J. Clinical observation of different minimally invasive surgeries for the treatment of impacted upper ureteral calculi. Pak J Med Sci. 2013; 29: 1358–1362. PMID: 24550953
- Bozkurt IH, Yonguc T, Arslan B, Degirmenci T, Gunlusoy B, Aydogdu O, et al. Minimally invasive surgical treatment for large impacted upper ureteral stones: Ureteroscopic lithotripsy or percutaneous nephrolithotomy? Can Urol Assoc J. 2015; 9: 122–125.
- Zhu HJ, Ye XJ, Xiao XR, Chen XL, Zhang QJ, Wang H. Retrograde, antegrade, and laparoscopic approaches to the management of large upper ureteral stones after shockwave lithotripsy failure: a four-year retrospective study. J Endourol. 2014; 28: 100–103. doi: 10.1089/end.2013.0391 PMID: 23914784
- Li H, Na WL, Li HY, Jiang Y, Gu XQ, Zhang MC, et al. Percutaneous nephrolithotomy versus ureteroscopic lithotomy for large (>15 mm) impacted upper ureteral stones in different locations: is the upper border of the fourth lumbar vertebra a good indication for choice of management method? J Endourol. 2013; 27: 1120–1125. doi: 10.1089/end.2012.0535 PMID: 23514547
- Juan YS, Shen JT, Li CC, Wang CJ, Chuang SM, Huang CH, et al. Comparison of percutaneous nephrolithotomy and ureteroscopic lithotripsy in the management of impacted, large, proximal ureteral stones. Kaohsiung J Med Sci. 2008; 24: 204–209. doi: <u>10.1016/S1607-551X(08)70118-9</u> PMID: 18424357
- Maheshwari PN, Oswal AT, Andankar M, Nanjappa KM, Bansal M. Is antegrade ureteroscopy better than retrograde ureteroscopy for impacted large upper ureteral calculi? J Endourol. 1999; 13: 441–444. doi: 10.1089/end.1999.13.441 PMID: 10479011
- 22. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535. doi: 10.1136/bmj.b2535 PMID: 19622551
- Phillips B, Ball C, Sackett D. Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence. CEBM. 2011. Available from: http://www.cebm.net/ocebm-levels-of-evidence/. Accessed December 15, 2016.
- Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. The Ottawa Hospital. Available from: <u>http://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp</u>. Accessed December 15, 2016.
- 25. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cocharane Collaboration. 2011. Available from: <u>http://handbook.cochrane.org./</u>. Accessed December 15, 2016.
- 26. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5: 13–13. doi: 10.1186/1471-2288-5-13 PMID: 15840177
- Roberts WW, Cadeddu JA, Micali S, et al. Ureteral stricture formation after removal of impacted calculi. J Uro. 1998; 159: 723–726.
- Hussain M, Ali B, Ahmed S, Zafar N, Naqvi SA, Rizvi SA. Prediction of renal function recovery in obstructive renal failure due to stones. J Pak Med Assoc. 1997; 47: 159–161. PMID: <u>9301168</u>
- **29.** Wright AE. Ureteroscopy and stones: Current status and future expectations. Word J Nephrol. 2014; 3: 243.
- Wright A, Rukin N, Smith D, De la Rosette J, Somani BK. 'Mini, ultra, micro'—nomenclature and cost of these new minimally invasive percutaneous nephrolithotomy (PCNL) techniques. Ther Adv Urol. 2016; 8: 142–146. doi: 10.1177/1756287215617674 PMID: 27034726

- Kyriazis I, Panagopoulos V, Kallidonis P, Özsoy M, Vasilas M, Liatsikos E. Complications in percutaneous nephrolithotomy. World J Urol. 2015; 33: 1069–1077. doi: 10.1007/s00345-014-1400-8 PMID: 25218854
- 32. Chow GK, Patterson DE, Blute ML, Segura JW. Ureteroscopy: effect of technology and technique on clinical practice. J Uro. 2003; 170: 99–102.
- Leijte JA, Oddens JR, Lock TM. Holmium laser lithotripsy for ureteral calculi: predictive factors for complications and success. J Endourol. 2008; 22: 257–260. doi: 10.1089/end.2007.0299 PMID: 18294030
- Seitz C, Tanovic E, Kikic Z, Fajkovic H. Impact of stone size, location, composition, impaction, and hydronephrosis on the efficacy of holmium: YAG-Laser ureterolithotripsy. Eur Urol. 2007; 52: 1751– 1759. doi: 10.1016/j.eururo.2007.04.029 PMID: 17459573
- Chen DY, Chen WC. Complications due to surgical treatment of ureteral calculi. Urological Science. 2010; 21: 81–87.
- Istanbulluoglu MO, Goren MR, Cicek T, Ozturk B, Ozkardes H. An alternative treatment for high-burden ureteral stones: percutaneous antegrade ureteroscopy. Urol Res. 2011; 39: 389–392. doi: 10.1007/ s00240-010-0351-9 PMID: 21193906